https://nf-health-economics.com/2026/03/30/review-of-managed-entry-agreements-for-high-cost-one-off-potentially-curative-therapies-a-framework-and-calculation-tool-to-determine-their-suitability/2026-03-30T08:21:16+00:00monthlyhttps://nf-health-economics.com/2026/03/09/review-of-cost-effectiveness-of-lovotibeglogene-autotemcel-lovo-cel-gene-therapy-for-patients-with-sickle-cell-disease-and-recurrent-vaso-occlusive-events-in-the-united-states/2026-03-09T09:12:00+00:00monthlyhttps://nf-health-economics.com/2026/02/09/review-of-surrogacy-and-the-valuation-of-atmps-taking-our-place-in-the-evidence-generation-assessment-continuum/2026-02-09T09:07:03+00:00monthlyhttps://nf-health-economics.com/2026/01/06/review-of-capturing-the-impact-of-constraints-on-the-cost-effectiveness-of-cell-and-gene-therapies-a-systematic-review/2026-01-06T09:21:36+00:00monthlyhttps://nf-health-economics.com/2025/11/10/preferences-for-advanced-therapy-medicinal-products-understanding-the-published-literature-on-the-value-of-innovative-health-interventions/2025-11-10T09:21:58+00:00monthlyhttps://nf-health-economics.com/2025/10/06/ending-the-confusion-defining-key-terms-in-value-assessment/2025-10-06T08:41:05+00:00monthlyhttps://nf-health-economics.com/2025/09/29/should-uncertainty-be-considered-a-value-attribute-in-its-own-right-or-as-an-inherent-component-of-other-attributes-as-part-of-value-assessment-frameworks/2025-09-29T08:59:56+00:00monthlyhttps://nf-health-economics.com/2025/09/15/value-attributes-of-advanced-therapy-medicinal-products-a-comprehensive-literature-review/2025-09-15T16:59:16+00:00monthlyhttps://nf-health-economics.com/2025/06/23/the-value-of-hope-the-case-against-inclusion-in-a-value-assessment-framework-for-advanced-therapies/2025-06-23T08:27:21+00:00monthlyhttps://nf-health-economics.com/2025/04/28/challenges-and-solutions-to-the-sustainability-of-gene-and-cell-therapies/2025-04-28T08:29:31+00:00monthlyhttps://nf-health-economics.com/2025/03/10/a-perspective-on-evolving-concept-of-value-in-health-economics-and-outcomes-research-emerging-tools-for-innovation-and-access-to-cell-and-gene-therapies-for-rare-diseases/2025-03-10T08:56:21+00:00monthlyhttps://nf-health-economics.com/2025/02/07/review-of-a-systematic-review-of-challenges-and-opportunities-in-the-implementation-of-managed-entry-agreements-for-advanced-therapy-medicinal-products/2025-02-07T09:31:45+00:00monthlyhttps://nf-health-economics.com/2024/12/09/linking-reimbursement-to-patient-benefits-for-advanced-therapy-medicinal-products-and-other-high-cost-innovations-policy-recommendations-for-outcomes-based-agreements-in-europe/2024-12-09T16:31:10+00:00monthlyhttps://nf-health-economics.com/2024/09/30/the-ispor-value-flower-application-to-advanced-therapy-medicinal-products/2024-09-30T09:46:53+00:00monthlyhttps://nf-health-economics.com/about/2024-09-15T15:51:40+00:00weekly0.6https://nf-health-economics.com/blog-2/2024-09-14T13:13:39+00:00weekly0.6https://nf-health-economics.com/contact/2024-09-14T10:53:12+00:00weekly0.6https://nf-health-economics.com/2024/09/02/a-case-study-of-the-challenges-of-demonstrating-cost-effectiveness-in-under-served-patient-populations-lecanemab-for-treating-mild-cognitive-impairment-or-mild-dementia-caused-by-alzheimers/2024-09-02T07:59:57+00:00monthlyhttps://nf-health-economics.com/2024/06/19/issues-challenges-and-opportunities-for-economic-evaluations-of-orphan-drugs-in-rare-diseases-an-umbrella-review/https://nf-health-economics.com/wp-content/uploads/2024/06/image-4.pngimage-4https://nf-health-economics.com/wp-content/uploads/2024/06/image-3.pngimage-3https://nf-health-economics.com/wp-content/uploads/2024/06/image-2.pngimage-2https://nf-health-economics.com/wp-content/uploads/2024/06/image-1.pngimage-1https://nf-health-economics.com/wp-content/uploads/2024/06/image.pngimage2024-06-19T19:21:15+00:00monthlyhttps://nf-health-economics.com/2024/06/17/identifying-value-elements-of-advanced-therapy-medicinal-products-an-opportunistic-review-of-stakeholder-responses-submitted-to-nice-as-part-of-reimbursement-decision-making/2024-06-17T08:59:24+00:00monthlyhttps://nf-health-economics.com/2024/04/17/value-assessment-of-advanced-therapies-improving-patient-access-to-innovative-treatments/2024-04-17T08:53:35+00:00monthlyhttps://nf-health-economics.com/2024/02/28/should-the-value-of-advanced-therapies-fall-under-a-subjective-or-objective-category-brief-philosophical-musings/2024-02-28T19:13:53+00:00monthlyhttps://nf-health-economics.com/2024/01/30/assessing-the-value-of-advanced-therapies/2024-01-30T18:56:18+00:00monthlyhttps://nf-health-economics.com/2022/09/01/key-questions-on-the-development-of-health-economics/2022-09-01T07:19:36+00:00monthlyhttps://nf-health-economics.com/2022/04/12/brief-considerations-on-the-value-assessment-of-advanced-therapy-medicinal-products/2022-04-12T09:21:24+00:00monthlyhttps://nf-health-economics.com/2021/09/05/the-potential-misnomer-of-health-economics-and-outcomes-research/2021-09-05T18:21:56+00:00monthlyhttps://nf-health-economics.com/2021/07/25/a-brief-consideration-of-the-lack-of-standardisation-in-health-economics/2021-07-25T19:55:48+00:00monthlyhttps://nf-health-economics.com/2021/02/06/how-should-value-in-healthcare-be-defined/2021-02-07T10:54:25+00:00monthlyhttps://nf-health-economics.com/2020/12/27/the-need-for-pragmatic-updates-to-the-nice-methods/2020-12-27T12:21:23+00:00monthlyhttps://nf-health-economics.com/2020/07/20/should-health-interventions-be-assessed-only-for-their-cost-effectiveness/2020-07-20T20:36:38+00:00monthlyhttps://nf-health-economics.com/2020/05/03/how-should-the-most-relevant-and-appropriate-health-outcomes-for-cost-effectiveness-analysis-be-determined/https://nf-health-economics.com/wp-content/uploads/2020/05/human-skeleton-163715_1280.jpghuman-skeleton-163715_12802020-05-03T14:41:57+00:00monthlyhttps://nf-health-economics.com/2020/04/20/should-clinical-trials-include-economic-endpoints/2020-05-03T14:27:39+00:00monthlyhttps://nf-health-economics.com/2020/04/20/thoughts-on-a-universal-health-economic-data-source/2020-05-03T14:27:26+00:00monthlyhttps://nf-health-economics.com/2020/04/20/the-need-for-alternative-data-sources-in-cost-effectiveness-analysis-in-health-economics/2020-05-03T14:27:08+00:00monthlyhttps://nf-health-economics.comdaily1.02026-03-30T08:21:16+00:00